These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32878571)

  • 1. Effects of atazanavir, darunavir, and raltegravir on fat and muscle among persons living with HIV.
    Adrian S; Miao H; Feng H; Scherzinger A; Nardini G; Beghetto B; Roncaglia E; Ligabue G; Milic J; Guaraldi G; Lake JE; Erlandson KM
    HIV Res Clin Pract; 2020 Aug; 21(4):91-98. PubMed ID: 32878571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
    Brown TT; Moser C; Currier JS; Ribaudo HJ; Rothenberg J; Kelesidis T; Yang O; Dubé MP; Murphy RL; Stein JH; McComsey GA
    J Infect Dis; 2015 Oct; 212(8):1241-9. PubMed ID: 25948863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.
    Kelesidis T; Tran TT; Stein JH; Brown TT; Moser C; Ribaudo HJ; Dube MP; Murphy R; Yang OO; Currier JS; McComsey GA
    Clin Infect Dis; 2015 Aug; 61(4):651-60. PubMed ID: 25904376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term cost analysis of raltegravir versus atazanavir + ritonavir or darunavir + ritonavir for treatment-naive adults with HIV-1 infection in the United States.
    Brogan AJ; Davis AE; Goodwin B
    PLoS One; 2018; 13(8):e0203293. PubMed ID: 30161205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study.
    Jao J; Yu W; Patel K; Miller TL; Karalius B; Geffner ME; DiMeglio LA; Mirza A; Chen JS; Silio M; McFarland EJ; Van Dyke RB; Jacobson D;
    HIV Med; 2018 Mar; 19(3):175-183. PubMed ID: 29159965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence, adherence, and all-cause healthcare costs in atazanavir- and darunavir-treated patients with human immunodeficiency virus in a real-world setting.
    Farr AM; Johnston SS; Ritchings C; Brouillette M; Rosenblatt L
    J Med Econ; 2016; 19(4):386-96. PubMed ID: 26640980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiretroviral Therapy Concentrations Differ in Gut vs. Lymph Node Tissues and Are Associated With HIV Viral Transcription by a Novel RT-ddPCR Assay.
    Lee SA; Telwatte S; Hatano H; Kashuba ADM; Cottrell ML; Hoh R; Liegler TJ; Stephenson S; Somsouk M; Hunt PW; Deeks SG; Yukl S; Savic RM
    J Acquir Immune Defic Syndr; 2020 Apr; 83(5):530-537. PubMed ID: 32168200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy.
    Calza L; Cafaggi M; Colangeli V; Borderi M; Barchi E; Lanzafame M; Nicole' S; Degli Antoni AM; Bon I; Re MC; Viale P
    Infect Dis (Lond); 2018 May; 50(5):352-360. PubMed ID: 29210336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.
    Madeddu G; Rusconi S; Cozzi-Lepri A; Di Giambenedetto S; Bonora S; Carbone A; De Luca A; Gianotti N; Di Biagio A; Antinori A;
    Infection; 2017 Aug; 45(4):521-528. PubMed ID: 28477212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial.
    Overton ET; Tebas P; Coate B; Ryan R; Perniciaro A; Dayaram YK; De La Rosa G; Baugh BP
    HIV Clin Trials; 2016 Mar; 17(2):72-7. PubMed ID: 26917112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s.
    McComsey GA; Moser C; Currier J; Ribaudo HJ; Paczuski P; Dubé MP; Kelesidis T; Rothenberg J; Stein JH; Brown TT
    Clin Infect Dis; 2016 Apr; 62(7):853-62. PubMed ID: 26797215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort.
    d'Arminio Monforte A; Lorenzini P; Cozzi-Lepri A; Mussini C; Castagna A; Baldelli F; Puoti M; Vichi F; Maddaloni A; Lo Caputo S; Gianotti N; Antinori A;
    HIV Clin Trials; 2018 Apr; 19(2):52-60. PubMed ID: 29493419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of nucleoside-sparing regimen based on raltegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients.
    Jabłonowska E; Pulik P; Kalinowska A; Gąsiorowski J; Parczewski M; Bociąga-Jasik M; Pulik Ł; Siwak E; Wójcik K
    J Med Virol; 2017 Dec; 89(12):2122-2129. PubMed ID: 28390164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual therapy with raltegravir plus a fixed dose combination of darunavir/ritonavir in people living with HIV in Argentina.
    Rombini F; Cecchini DM; Ballivian J; Huberman M; Urueña A; Cassetti I
    Rev Esp Quimioter; 2021 Feb; 34(1):56-60. PubMed ID: 33267555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients.
    Nishijima T; Hamada Y; Watanabe K; Komatsu H; Kinai E; Tsukada K; Teruya K; Gatanaga H; Kikuchi Y; Oka S
    PLoS One; 2013; 8(10):e77268. PubMed ID: 24130871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.
    Ofotokun I; Na LH; Landovitz RJ; Ribaudo HJ; McComsey GA; Godfrey C; Aweeka F; Cohn SE; Sagar M; Kuritzkes DR; Brown TT; Patterson KB; Para MF; Leavitt RY; Villasis-Keever A; Baugh BP; Lennox JL; Currier JS;
    Clin Infect Dis; 2015 Jun; 60(12):1842-51. PubMed ID: 25767256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial.
    Avihingsanon A; Hughes MD; Salata R; Godfrey C; McCarthy C; Mugyenyi P; Hogg E; Gross R; Cardoso SW; Bukuru A; Makanga M; Badal-Aesen S; Mave V; Ndege BW; Fontain SN; Samaneka W; Secours R; Van Schalkwyk M; Mngqibisa R; Mohapi L; Valencia J; Sugandhavesa P; Montalban E; Munyanga C; Chagomerana M; Santos BR; Kumarasamy N; Kanyama C; Schooley RT; Mellors JW; Wallis CL; Collier AC; Grinsztejn B;
    J Int AIDS Soc; 2022 Jun; 25(6):e25905. PubMed ID: 36039892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s.
    Kelesidis T; Tran TTT; Brown TT; Moser C; Ribaudo HJ; Dube MP; Yang OO; McComsey GA; Stein JH; Currier JS
    Antivir Ther; 2017; 22(2):113-126. PubMed ID: 27661466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct Lipidomic Signatures in People Living With HIV: Combined Analysis of ACTG 5260s and MACS/WIHS.
    Jao J; Balmert LC; Sun S; McComsey GA; Brown TT; Tien PC; Currier JS; Stein JH; Qiu Y; LeRoith D; Kurland IJ
    J Clin Endocrinol Metab; 2022 Jan; 107(1):119-135. PubMed ID: 34498048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis.
    Menshawy A; Ismail A; Abushouk AI; Ahmed H; Menshawy E; Elmaraezy A; Gadelkarim M; Abdel-Maboud M; Attia A; Negida A
    Arch Virol; 2017 Aug; 162(8):2181-2190. PubMed ID: 28361290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.